Knee osteoarthritis (KOA) is a common degenerative joint condition that can cause persistent pain, stiffness, and reduced mobility. Everyday activities such as climbing stairs, walking, or standing up from a seated position may become increasingly difficult as symptoms progress.
Among injectable treatment options, platelet-rich plasma (PRP) and hyaluronic acid (HA) have received attention for their potential role in managing knee osteoarthritis. But how do these two approaches compare, and what does the clinical evidence suggest?
Clinical Evidence: PRP vs. Hyaluronic Acid
A 2020 meta-analysis published in the Journal of Orthopaedic Surgery and Research compared the clinical outcomes of PRP and hyaluronic acid injections in patients with knee osteoarthritis.
The analysis included 20 randomized controlled trials (RCTs) and evaluated pain, joint function, stiffness, and adverse events across different follow-up periods.
Key findings included:
- Pain reduction: PRP demonstrated greater improvements in WOMAC pain and VAS scores at 6 and 12 months compared with HA.
- Functional improvement: WOMAC function scores favored PRP at 1, 3, 6, and 12 months.
- Overall outcomes: WOMAC total scores favored PRP at 6 and 12 months, while IKDC scores showed significant advantages at 3 and 6 months.
- Safety: No significant difference in adverse events was found between PRP and HA.
However, not all outcome measures showed significant differences. The Lequesne Index and KOOS scores were comparable between treatment groups.
Overall, the findings suggest that PRP may offer advantages over hyaluronic acid for longer-term pain reduction and functional improvement in patients with knee osteoarthritis.
What This Means for Foot and Knee Specialists
The findings provide clinical context for physicians considering injectable treatment options for patients with symptomatic knee osteoarthritis. While both PRP and hyaluronic acid are used in clinical practice, this meta-analysis suggests PRP may offer greater improvements in pain and function over longer follow-up periods.
Treatment selection should remain individualized, taking into account disease severity, patient expectations, clinical history, and available treatment options. Further research using standardized PRP preparation protocols and outcome measures is needed to better establish optimal treatment approaches.
Tropocells® PRP: Supporting Regenerative Procedures
Tropocells® PRP by Epimed is designed to facilitate office-based PRP preparation using patented separator gel technology. The system concentrates platelets while removing 99.9% of red blood cells and 95% of neutrophils, while preserving monocytes and lymphocytes.
Key features include:
- Approximately 80% platelet recovery.
- Single-spin preparation in less than 15 minutes.
- Sterile, closed system.
- Available in 11 mL, and 22 mL kits.
- FDA-cleared 510(k) medical device.






